Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
299 studies found for:    IL12B
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Ustekinumab 90 mg;   Drug: Ustekinumab 4.5 mg/kg;   Drug: Placebo SC;   Drug: Placebo IV
2 Recruiting Efficacy, Safety and Pharmacokinetics of BI 655066 in Patients With Active, Moderate-to-severe Crohn's Disease.
Condition: Crohn Disease
Interventions: Drug: BI 655066 (high dose);   Drug: BI 655066 (low dose);   Drug: BI 655066 one dose;   Drug: placebo dose
3 Completed
Has Results
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
Condition: Plaque-Type Psoriasis
Intervention: Drug: Apremilast
4 Recruiting Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: Ustekinumab;   Other: Placebo
5 Unknown  Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
Conditions: Breast Cancer;   Colorectal Cancer;   Melanoma (Skin)
Interventions: Biological: Corynebacterium granulosum P40;   Procedure: adjuvant therapy
6 Completed
Has Results
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
Condition: Arthritis, Psoriatic
Interventions: Drug: Placebo;   Drug: Ustekinumab 45 mg;   Drug: Ustekinumab 90 mg
7 Completed
Has Results
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: CNTO 1275
8 Completed
Has Results
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
Condition: Arthritis, Psoriatic
Interventions: Drug: placebo;   Drug: ustekinumab 45 mg;   Drug: ustekinumab 90 mg
9 Completed
Has Results
Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®
Conditions: Aging;   Pain
Interventions: Device: Evolence;   Device: Lidocaine;   Drug: topical anesthetic
10 Completed Exhaled Nitric Oxide and Airway Caliber in Children With Asthma
Condition: Asthma in Children
Intervention:
11 Unknown  Maternal Serum Cytokine Levels and Angiogenic Factor Levels in IVF vs Spontaneously Conceived Pregnancies
Condition: Infertility
Intervention:
12 Completed Rituximab for Pulmonary Sarcoidosis
Condition: Sarcoidosis
Intervention: Drug: Rituximab
13 Completed Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects
Condition: Healthy
Interventions: Drug: BIBR 796 BS, low dose;   Drug: BIBR 796 BS, high dose;   Drug: Placebo;   Drug: Lipopolysaccharide
14 Recruiting IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection
Condition: HIV Reservoirs
Intervention: Other: Blood sample and recto-colic biopsies
15 Not yet recruiting Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: DSP-5423P
16 Completed
Has Results
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
Condition: Dry Eye Syndromes
Interventions: Drug: CP-690,550 Eye drops;   Drug: CP-690,550 Eye drops-vehicle;   Drug: Sodium Hyaluronate
17 Completed PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection
Condition: HIV Infection
Interventions: Biological: PENNVAX-B;   Biological: GENEVAX IL-12-4532;   Biological: PLACEBO;   Biological: IL-15 adjuvant
18 Completed Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Cancer Recurrent
Intervention: Radiation: 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
19 Completed Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Biological: rituximab;   Biological: recombinant interleukin-12;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
20 Completed Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-B;   Biological: IL-12 DNA plasmids

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years